Haemonetics (NYSE: HAE) reported Q2 EPS of $0.48, $0.07 better than the analyst estimate of $0.41. Revenue for the quarter came in at $225 million versus the consensus estimate of $219.26 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.